Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus MAXAIR.
BRONKOSOL vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator